Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the pharma industry. This time, you get to discover five hand-picked startups developing cardiovascular applications.
Out of 522, the Global Startup Heat Map highlights 5 Top Startups developing Cardiovascular Applications
The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering 2 093 000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies & relevant startups within a specific field in just a few clicks.
The Global Startup Heat Map below reveals the distribution of the 522 exemplary startups & scaleups we analyzed for this research. Further, it highlights five pharma startups that we hand-picked based on criteria such as founding year, location, funding raised, and more. You get to explore the solutions of these five startups & scaleups in this report. For insights on the other 517 cardiovascular solutions, get in touch with us.
Click to download
Anthos Therapeutics advances Cardiovascular Therapies
Founding Year: 2018
Location: Cambridge, USA
Partner for: Metabolic Diseases Management
US-based startup Anthos Therapeutics develops and commercializes therapies for people with cardiovascular diseases. The startup’s solution uses Abelacimab, an investigational monoclonal antibody that is highly suppressive of the novel antithrombotic target Factor XI and Factor Xla. In this way, it serves to protect arteries through its anticoagulant properties and significantly reduce the risk of bleeding. Moreover, compared to existing anticoagulants, Factor XI inhibitors offer better protection from thromboembolic events and reduce clinically significant bleeding risk through their hemostasis-sparing anticoagulation properties.
ResoTher Pharma formulates Peptide-based Drugs
Founding Year: 2016
Location: Holte, Denmark
Funding: USD 1,75 M
Partner for: Resolution Therapy
Danish startup ResoTher Pharma offers peptide therapeutics for treating cardiovascular disorders. The startup develops peptide-based drugs from the endogenous immunomodulator Annexin A1 as resolution therapy. Its patented peptide drugs target the FPR2 receptor, a G-protein coupled receptor on the surface of leukocytes. The drug functions by imitating the body’s natural response to heal inflammation and initiating tissue repair. Moreover, the startup’s peptide-based drugs provide treatments for diseases where neutrophil-driven inflammation plays a critical pathological role.
LianBio develops Cardiovascular Therapeutics
Founding Year: 2019
Location: Shanghai, China
Funding: USD 310 M
Partner for: Kidney Disease Management
Chinese scaleup LianBio engages in innovative therapeutic discoveries. Its therapeutic pipeline includes a cardiovascular solution based on Mavacamten, a small molecule therapeutic that reversibly binds to myosin. This directly targets the excess contractility and impaired relaxation underlying hypertrophic cardiomyopathy (HCM). Additionally, the startup’s pipeline includes therapeutics for oncological, respiratory, opthalmological, and inflammatory diseases. LianBio’s cardiovascular solution treats patients who suffer from debilitating hypertrophic cardiomyopathy.
Dinaqor builds In-Vivo Gene Editing Platforms
Founding Year: 2019
Location: Pfaffikon, Switzerland
Partner for: Cardiological Gene Therapy
Swiss startup Dinaqor makes a genetic medicine platform to cure severe and inherited forms of heart disease. The platform features proprietary engineered heart tissue (EHT) technology that is based on human-induced pluripotent stem cell cardiomyocytes. It also contains a proprietary loco-regional perfusion (LRP) system that delivers gene therapy directly to the heart tissue. Besides this, Dianqor’s pipeline of genetic treatments targets hypertrophic, arrhythmogenic, and dilated cardiomyopathy as well as restorative therapy for heart failure.
Saillant Therapeutics offers Small Molecule-based Therapies
Founding Year: 2018
Location: Nijmegen, Netherlands
Partner for: Alzheimer’s Disease Treatment
Dutch startup Saillant Therapeutics provides small molecule-based therapies against acute ischemic stroke and heart failure. Saillant Therapeutics’ pharmacological platform, ST-01, together with corresponding proprietary therapeutic leads, activates a cellular master regulator, controlling adaptive functions in cells and tissues. This regulatory mechanism prevents tissue damage to organs in the cardiovascular system and the central nervous system and also inhibits virus replication. This way, the startup’s platform offers therapeutics that counter tissue loss and treat viral diseases.
Discover more Pharma Startups
Pharma startups such as the examples highlighted in this report focus on cardiovascular therapeutics, gene editing platforms, small molecule-based therapies as well as peptide-based drugs. While all of these technologies play a major role in advancing the pharma industry, they only represent the tip of the iceberg. To explore pharma technologies in more detail, simply let us look into your areas of interest. For a more general overview, download our free Pharma Innovation Report to save your time and improve strategic decision-making.
